Novo Nordisk

Valby, Denmark – October 18, 2026 -- H. Lundbeck A/S plans to install former Novo Nordisk CEO Lars Fruergaard Jørgensen as Chair of its Board after the 2027 Annual General Meeting (AGM), succeeding Dorothea Wenzel, who will step down at that meeting.

Jørgensen joins the Board as observer on 10 November 2026

Jørgensen will take an observer seat on 10 November 2026 and will remain in that role until the AGM 2027. At that meeting he is expected to be formally elected as a Board member, subject to shareholder approval. The Board intends to elect him Chair thereafter. Nominated candidates will be listed in the notice convening the AGM 2027.

Plainsboro, New Jersey – – September 30, 2026 -- Adults with overweight or obesity who switched from injectable GLP-1 therapies to the oral Wegovy pill lost an average of 4.0 kg (8.8 lb) over three months, according to new real-world data from Novo Nordisk's OCTANE study presented at the 62nd Annual Meeting of the European Association for the Study of Diabetes in Milan on September 30, 2026.

Patients switching to the oral formulation saw rapid weight-loss gains after three months

The retrospective analysis of 194 patients on the Ro telehealth platform found that 40.7% achieved weight loss of 5% or more within three months of switching from injectable semaglutide or tirzepatide to once-daily oral semaglutide (p0.001). The proportion of participants classified with a BMI of 30 kg/m2 or higher fell by 21.6 percentage points, dropping from 87.1% at baseline to 65.5% at the three-month mark.

Plainsboro, N.J. – – September 29, 2026 -- Novo Nordisk reported that adults with type 2 diabetes who escalated their semaglutide dose to 2 mg showed a statistically significant 6% lower risk of major adverse cardiovascular events (MACE) compared with patients who switched to tirzepatide, according to real-world data presented at the European Association for the Study of Diabetes (EASD) Annual Meeting 2026 in Milan.

Retrospective analysis covers 636,525 patients on semaglutide 1 mg

The COMPETE SWITCH Cardiovascular study used Komodo Health's Healthcare Map claims database, spanning January 2018 to September 2025, to compare outcomes for patients escalating from semaglutide 1 mg to 2 mg against those switching to tirzepatide at doses up to 15 mg. The cardiovascular cohort included 185,705 adults who escalated to semaglutide 2 mg and 23,104 who switched to tirzepatide, tracked via an intention-to-treat approach for death, heart attack, and stroke.

Indianapolis – September 29, 2026 -- Eli Lilly and Company (NYSE: LLY) reported that its oral GLP-1 drug Foundayo (orforglipron) at 17.2 mg produced 1.5% greater weight loss and 0.3% greater A1C reduction than oral semaglutide 25 mg over 52 weeks in adults with type 2 diabetes, based on an indirect treatment comparison presented at the 62nd Annual Meeting of the European Association for the Study of Diabetes in Milan.

Indirect analysis draws on ACHIEVE-3 and PIONEER PLUS trial data

The comparison, covariate-adjusted for gender, age, baseline A1C and baseline weight, found weight-loss differences ranging from 1.5% to 2.4% and A1C reductions of 0.3% to 0.6% in favor of Foundayo 17.2 mg across multiple statistical methods. The 95% confidence interval for weight loss was -2.7% to -0.2%, and for A1C reduction was -0.6% to -0.1%.

Shanghai – – September 29, 2026 -- Hengrui Pharma has licensed its investigational obesity and diabetes drug HRS-1596 to Novo Nordisk in a deal worth up to 2.6 billion US dollars, including a 300 million dollar upfront payment.

Novo secures global rights excluding Greater China

Under the agreement, Novo obtains exclusive rights to develop, manufacture and commercialise HRS-1596 worldwide, excluding the Chinese mainland, Hong Kong SAR, Macao SAR and Taiwan Region. Hengrui Pharma retains eligibility for royalties on net sales of the drug within Novo's licensed territory, on top of the milestone-based payments tied to development, regulatory and commercial targets.

Uppsala – September 25, 2026 -- Nanexa AB has signed a global exclusive license and collaboration agreement with Novo Nordisk worth up to EUR 1.165 billion, granting the Danish pharmaceutical giant rights to the Swedish company's PharmaShell atomic layer deposition (ALD) drug delivery platform for peptide-based treatments in obesity, type 2 diabetes and other cardiometabolic diseases.

Novo Nordisk gains rights to up to five development programs under the deal

The agreement covers formulations targeting monthly and quarterly administration frequencies, reducing dosing burden for chronic metabolic and cardiovascular disease patients. Novo Nordisk will lead global development and commercialization across all programs, while Nanexa retains eligibility for milestone-based payments tied to development, regulatory and sales achievements.

Seattle – September 25, 2026 -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) announced that President and CEO Steven Quay, M.D., Ph.D., will serve as a panelist at the 13th Aging Research and Drug Discovery Meeting (ARDD 2026), scheduled for October 1-3, 2026, at the David Rubenstein Treehouse at Harvard University in Boston.

Quay joins regulatory and academic leaders to discuss clinical pathways for aging-related diseases

The panel, titled "Clinical Trials in Diseases of Aging: From Evidence to New Therapeutics and Regulatory Pathways," is set for Thursday, September 25, 2026, from 11:20 a.m. to 12:00 p.m. ET. The session will be moderated by Sebastien Thuault, Editor at Nature Medicine, and will include Jill Lee, Director of Regulatory Policy & Intelligence at Novo Nordisk; Calum MacRae, Professor at Mass General Brigham; and Steve Horvath, Professor at UCLA.

Boston – September 21, 2026 -- Cellular Intelligence, a Boston-based AI company building a universal foundation model of cell signaling, has appointed Turing Award laureate Yann LeCun, Moderna co-founder Robert "Bob" Langer, BioInnovation Institute CEO Jens Nielsen and Helmholtz Munich computational health director Fabian Theis to its Scientific Advisory Board. Langer also joins the company's Board of Directors as an observer.

Las Vegas – September 20, 2026 -- The paroxysmal nocturnal hemoglobinuria (PNH) market across the seven major markets was valued at approximately $1.5 billion in 2025 and is projected to grow at a compound annual growth rate of 7.1% through 2036, according to DelveInsight.

Regeneron's pozelimab-cemdisiran combination leads next wave of PNH therapies

Pozelimab, a fully human anti-C5 monoclonal antibody developed on Regeneron's VelocImmune platform, is expected to generate the highest revenue among emerging PNH therapies in the seven major markets. The drug is being tested in combination with Alnylam's siRNA therapy cemdisiran; Regeneron has said Phase III results in PNH are anticipated in the fourth quarter of 2026 or the first quarter of 2027.

Las Vegas – – September 16, 2026 -- The obesity therapeutics market across the seven major markets was valued at approximately USD 16 billion in 2025 and is projected to grow at a 27% CAGR through 2036, according to DelveInsight, as a wave of next-generation candidates threatens to disrupt the Eli Lilly-Novo Nordisk duopoly.

Oral GLP-1 Therapies Accelerate Patient Uptake

Novo Nordisk's oral WEGOVY surpassed 5 million cumulative U.S. prescriptions within 30 weeks of launch, while Eli Lilly's oral FOUNDAYO (orforglipron) gained significant traction among patients initiating obesity treatment by mid-2026. Aparna Thakur, Project Manager of Forecasting & Analytics at DelveInsight, said FOUNDAYO's once-daily oral formulation positions it for rapid uptake as a more convenient alternative to injectable therapies.